Gallium-transferrin binding in treated and untreated Parkinson's disease

Sarah J. Winsper, Richard A. Armstrong*, Paul S. Hodgkins, John A. Blair

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The binding of gallium (Ga) to transferrin (Tf) was studied in plasma from control patients, in patients with untreated Parkinson's disease (PD) and in patients with PD treated either with levodopa (L-dopa) alone or in combination with selegiline. Mean percentage Ga-Tf binding was significantly reduced in untreated and treated PD compared with controls. Binding, however, was significantly greater in treated than in untreated patients. There was no difference in binding between patients treated with L-dopa alone and those treated with L-dopa and selegiline. The data support the hypothesis that oxidation reactions may be of pathogenic significance in PD.
Original languageEnglish
Pages (from-to)709-711
Number of pages3
JournalNeuroReport
Volume8
Issue number3
Publication statusPublished - 10 Feb 1997

Fingerprint

Gallium
Transferrin
Parkinson Disease
Levodopa
Selegiline

Keywords

  • gallium-transferrin binding
  • L-dopa
  • oxidation reaction
  • Parkinson's disease
  • selegiline
  • transferrin

Cite this

Winsper, S. J., Armstrong, R. A., Hodgkins, P. S., & Blair, J. A. (1997). Gallium-transferrin binding in treated and untreated Parkinson's disease. NeuroReport, 8(3), 709-711.
Winsper, Sarah J. ; Armstrong, Richard A. ; Hodgkins, Paul S. ; Blair, John A. / Gallium-transferrin binding in treated and untreated Parkinson's disease. In: NeuroReport. 1997 ; Vol. 8, No. 3. pp. 709-711.
@article{012c886cddbc463c943248682b21a993,
title = "Gallium-transferrin binding in treated and untreated Parkinson's disease",
abstract = "The binding of gallium (Ga) to transferrin (Tf) was studied in plasma from control patients, in patients with untreated Parkinson's disease (PD) and in patients with PD treated either with levodopa (L-dopa) alone or in combination with selegiline. Mean percentage Ga-Tf binding was significantly reduced in untreated and treated PD compared with controls. Binding, however, was significantly greater in treated than in untreated patients. There was no difference in binding between patients treated with L-dopa alone and those treated with L-dopa and selegiline. The data support the hypothesis that oxidation reactions may be of pathogenic significance in PD.",
keywords = "gallium-transferrin binding, L-dopa, oxidation reaction, Parkinson's disease, selegiline, transferrin",
author = "Winsper, {Sarah J.} and Armstrong, {Richard A.} and Hodgkins, {Paul S.} and Blair, {John A.}",
year = "1997",
month = "2",
day = "10",
language = "English",
volume = "8",
pages = "709--711",
journal = "NeuroReport",
issn = "0959-4965",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Winsper, SJ, Armstrong, RA, Hodgkins, PS & Blair, JA 1997, 'Gallium-transferrin binding in treated and untreated Parkinson's disease', NeuroReport, vol. 8, no. 3, pp. 709-711.

Gallium-transferrin binding in treated and untreated Parkinson's disease. / Winsper, Sarah J.; Armstrong, Richard A.; Hodgkins, Paul S.; Blair, John A.

In: NeuroReport, Vol. 8, No. 3, 10.02.1997, p. 709-711.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gallium-transferrin binding in treated and untreated Parkinson's disease

AU - Winsper, Sarah J.

AU - Armstrong, Richard A.

AU - Hodgkins, Paul S.

AU - Blair, John A.

PY - 1997/2/10

Y1 - 1997/2/10

N2 - The binding of gallium (Ga) to transferrin (Tf) was studied in plasma from control patients, in patients with untreated Parkinson's disease (PD) and in patients with PD treated either with levodopa (L-dopa) alone or in combination with selegiline. Mean percentage Ga-Tf binding was significantly reduced in untreated and treated PD compared with controls. Binding, however, was significantly greater in treated than in untreated patients. There was no difference in binding between patients treated with L-dopa alone and those treated with L-dopa and selegiline. The data support the hypothesis that oxidation reactions may be of pathogenic significance in PD.

AB - The binding of gallium (Ga) to transferrin (Tf) was studied in plasma from control patients, in patients with untreated Parkinson's disease (PD) and in patients with PD treated either with levodopa (L-dopa) alone or in combination with selegiline. Mean percentage Ga-Tf binding was significantly reduced in untreated and treated PD compared with controls. Binding, however, was significantly greater in treated than in untreated patients. There was no difference in binding between patients treated with L-dopa alone and those treated with L-dopa and selegiline. The data support the hypothesis that oxidation reactions may be of pathogenic significance in PD.

KW - gallium-transferrin binding

KW - L-dopa

KW - oxidation reaction

KW - Parkinson's disease

KW - selegiline

KW - transferrin

UR - http://www.scopus.com/inward/record.url?scp=0030972320&partnerID=8YFLogxK

UR - http://journals.lww.com/neuroreport/Abstract/1997/02100/Gallium_transferrin_binding_in_treated_and.26.aspx

M3 - Article

C2 - 9106752

VL - 8

SP - 709

EP - 711

JO - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 3

ER -

Winsper SJ, Armstrong RA, Hodgkins PS, Blair JA. Gallium-transferrin binding in treated and untreated Parkinson's disease. NeuroReport. 1997 Feb 10;8(3):709-711.